DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab plus tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative head and neck squamous cell carcinoma (LA-HNSCC)

被引：0
|
作者：
Keilholz, Ulrich
Gauler, Thomas Christoph
Stromberger, Carmen
Kofla, Grzegorz
De Wit, Maike
Mette, Ramona
Burock, Susen
Klinghammer, Konrad Friedrich
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Charite Comprehens Canc Ctr, Berlin Inst Hlth, Berlin, Germany
[5] Univ Duisburg Essen, Univ Hosp Essen, Dept Med, West German Canc Ctr, Essen, Germany
[6] Charite Univ Med Berlin, Dept Radiat Oncol, Ctr Comprehens Canc, Berlin, Germany
[7] Charite Univ Med Berlin, Dept Hematol Oncol & Canc Immunol, Campus Virchow Klinikum, Berlin, Germany
[8] Berlin Inst Hlth, Berlin, Germany
[9] Vivantes, Berlin, Germany
[10] Charite Comprehens Canc Ctr, Berlin Inst Hlth, EORTC Liaison Off, Berlin, Germany
[11] Charite Univ Med Berlin, Charite Comprehens Canc Ctr, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2611
引用
收藏
页数：1
相关论文
共 15 条
  • [1] DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC-Results of the preplanned feasibility interim analysis.
    Klinghammer, Konrad Friedrich
    Gauler, Thomas Christoph
    Stromberger, Carmen
    Kofla, Grzegorz
    de Wit, Maike
    Gollrad, Johannes
    Rauer, Izabella
    Martus, Peter
    Tinhofer, Inge
    Budach, Volker
    Keilholz, Ulrich
    Burock, Susen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
    Kim, Chang Gon
    Hong, Min Hee
    Kim, Dahee
    Lee, Brian Hyohyoung
    Kim, Hyunwook
    Ock, Chan-Young
    Kelly, Geoffrey
    Bang, Yoon Ji
    Kim, Gamin
    Lee, Jung Eun
    Kim, Chaeyeon
    Kim, Se-Heon
    Hong, Hyun Jun
    Park, Young Min
    Sim, Nam Suk
    Park, Heejung
    Park, Jin Woo
    Lee, Chang Geol
    Kim, Kyung Hwan
    Park, Goeun
    Jung, Inkyung
    Han, Dawoon
    Kim, Jong Hoon
    Cha, Junha
    Lee, Insuk
    Kang, Mingu
    Song, Heon
    Oum, Chiyoon
    Kim, Seulki
    Kim, Sukjun
    Lim, Yoojoo
    Kim-Schulze, Seunghee
    Merad, Miriam
    Yoon, Sun Och
    Kim, Hyun Je
    Koh, Yoon Woo
    Kim, Hye Ryun
    CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2097 - 2110
  • [3] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Licitra, Lisa F.
    Haddad, Robert I.
    Even, Caroline
    Tahara, Makoto
    Dvorkin, Mikhail
    Ciuleanu, Tudor-Eliade
    Clement, Paul M.
    Mesia, Ricard
    Kutukova, Svetlana I.
    Zholudeva, Lyubov
    Daste, Amaury
    Caballero, Javier Daroqui
    Keam, Bhumsuk
    Vynnychenko, Ihor
    Lafond, Cedrik
    Shetty, Jagdish
    Morsli, Nassim
    Mann, Helen
    Fayette, Jerome
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] A randomized, multicenter, open phase II study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
    Koh, Youngil
    Lee, Keun-Wook
    Kim, Sung-Bae
    Park, Kyong Hwa
    Shin, Sang Won
    Kang, Jin Hyoung
    Keam, Bhumsuk
    Lee, Se-Hoon
    Heo, Dae Seog
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR
    Siu, L.
    Even, C.
    Mesia, R.
    Daste, A.
    Krauss, J.
    Saba, N. F.
    Nabell, L.
    Ready, N. E.
    Brana Garcia, I.
    Kotecki, N.
    Zandberg, D. P.
    Gilbert, J.
    Mehanna, H.
    Jarkowski, A.
    Melillo, G.
    Armstrong, J. M.
    Fayette, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1307 - 1307
  • [6] Clinical/biomarker data for neoadjuvant tislelizumab (TIS) plus chemotherapy (Chemo) in resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A single-arm, phase II trial
    Li, Q.
    Cai, L.
    Kuang, D.
    Pan, C.
    Zhao, J.
    Huang, P.
    He, C.
    Xu, K.
    Liu, D.
    Long, G.
    Liu, Z.
    Hu, G.
    Lu, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S621 - S622
  • [7] A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Saba, Nabil F.
    Adkins, Douglas
    Wang, Ying
    He, Yi
    Paradise, Elsa
    Cohen, Roger B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Long term results of a phase II trial of Induction Chemotherapy with Uracil-Ftegafur (UFT), Vinorelbine and Cisplatin (UFTVP) followed by Radiotherapy concomitant with UFT and Carboplatin (RT/UFTJ) in Non-Resectable Locally Advanced (Stage IV-B) Squamous Cell Head and Neck Carcinoma
    Fernando Rivera
    María E Vega-Villegas
    Marta F. López-Brea
    Almudena García-Castaño
    Ana de Juan
    Francisco Javier Ramos
    Antonio Collado
    Piedad Galdós
    Antonio Rubio
    Adolfo del Valle
    Julio Rama
    Marta Mayorga
    Jaime Sanz-Ortiz
    Clinical and Translational Oncology, 2007, 9 : 202 - 202
  • [9] A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results
    Cohen, E. E. W.
    Harrington, K. J.
    Hong, D. S.
    Mesia, R.
    Brana, I.
    Perez Segura, P.
    Wise-Draper, T.
    Scott, M. L.
    Mitchell, P. D.
    Mugundu, G. M.
    McCoon, P.
    Cook, C. E.
    Mehta, M.
    Keilholz, U.
    ANNALS OF ONCOLOGY, 2018, 29 : 372 - 372
  • [10] An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC)
    Bang, Y-J
    Goff, L. W.
    Wasserstrom, H.
    Yang, J.
    Mi, G.
    Karasarides, M.
    Reck, M.
    ANNALS OF ONCOLOGY, 2016, 27
12